AVBPArriVent BioPharma, Inc.
$16.72-5.3% 1Y
$16.72
$15.1252 weeks$33.83
AVBP as reported
- Net income
- −$164M
Net income · +20% year on year · trailing twelve months to Q2 2026
- EPS
- −$3.62
EPS · −10.0% year on year · trailing twelve months to Q2 2026
Details›
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Net income | −$164M | +20% | Q2 2026 |
| EPS | −$3.62 | −10.0% | Q2 2026 |
| ROE | −48% | n/a | Q2 2026 |
| ROA | −45% | n/a | Q2 2026 |
Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.
ArriVent BioPharma, Inc. (AVBP) · Net incomeNet incomeArriVent BioPharma, Inc. (AVBP)
On our screens:Most shorted stocks
Biotechnology
The closest names by size in the same industry